PaperNeoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
References (40)
- et al.
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm
Ann Oncol
(1991) - et al.
Neoadjuvant chemotherapy in operable breast cancer
Eur J Cancer
(1991) - et al.
Local control of operable breast cancer after radiotherapy alone
Eur J Cancer
(1990) - et al.
Radical radiation therapy of breast cancer
Int J Radiat Oncol Biol Phys
(1980) - et al.
Breast irradiation in the lateral decubitus position: technique of the Institut Curie
Radiother Oncol
(1991) - et al.
External irradiation prior to conservative surgery for breast cancer treatment
Int J Radiat Oncol Biol Phys
(1991) - et al.
Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure
Int J Radiatt Oncol Biol Phys
(1989) - et al.
Comparison of Halsted mastectomy with quadrantectomy; axillary dissection and radiotherapy in early breast cancer: long term results
Eur J Cancer Clin Oncol
(1986) - et al.
Predictors of local control following radiotherapy alone for breast cancer
Int J Radiat Oncol Biol Phys
(1991) - et al.
Effect of delay in radiation in the combined modality treatment of breast cancer
Int J Radiat Oncol Biol Phys
(1993)
Should surgery remain the initial treatment of “operable” breast cancer?
Eur J Cancer
Concepts for treatment of micrometastases in murine systems
Am J Roentgenol
Surgical adjuvant chemotherapy of metastatic murine tumors
Cancer
A role for chemotherapy as an adjunct to surgery
Cancer Res
Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases
Cancer Res
The cell cycle and chemotherapy of cancer
The potential for murine tumor models in surgical adjuvant chemotherapy
Cancer Chemother Rep
Success and failure in the treatment of solid tumors
Cancer Chemother Rep
Surgery, cancer chemotherapy, host defenses and tumor size
J Natl Cancer Inst
Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells
Cited by (419)
Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study
2022, Annals of Medicine and SurgeryA Review of the Impact of Neoadjuvant Chemotherapy on Breast Surgery Practice and Outcomes
2019, Clinical Breast CancerCitation Excerpt :The timing of delivery of NAC also facilitates other aspects of care, such as genetic testing, fertility preservation, and immediate breast reconstruction.14 Several studies have demonstrated an increased use of BCS compared with mastectomy in patients treated with NAC; the NSABP-B18 trial demonstrated an increased rate of BCS from 60% to 68% post-neoadjuvant therapy; trials from the Royal Marsden reported an increase from 78% to 89% and trials from the Curie Institute reported an increased BCS rate of 82% from 77%.15-17 The use of BCS in patients receiving chemotherapy increased from 49.6% in 2005 to 69.2% in 2014 in our institution.
Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy
2019, Journal of Gynecology Obstetrics and Human ReproductionAdjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes
2019, Seminars in OncologyCitation Excerpt :A similar treatment strategy in 52 patients with noninflammatory breast cancer treated with 3 cycles of 5-fluorouracil (5-FU) + adriamycin + cyclophosphamide plus Bacillus Calmette-Guérin prior to local radiation or surgery followed by radiation achieved an objective response rate to chemotherapy of 82% with 40% actuarial 5-year survival [110]. Trials comparing the same regimen administered either pre- or postoperatively [88-90,110] demonstrated neoadjuvant therapy could be administered safely. Furthermore, although adjuvant therapy failed to improve recurrence-free and overall survival, other end points emerged as valuable, including improvements in breast conservation rates [88-90,104-106,110].